Previous Close | 1.3800 |
Open | 1.3400 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 1.3400 - 1.6000 |
52 Week Range | 1.1300 - 6.3000 |
Volume | |
Avg. Volume | 358,259 |
Market Cap | 2.203M |
Beta (5Y Monthly) | 2.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.6500 |
Earnings Date | Jul 26, 2024 - Aug 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
WASHINGTON (Reuters) -The former CEO of healthcare software company SCWorx Corp was found guilty of investor fraud for falsely stating the company was becoming a major supplier of COVID-19 rapid tests early in the pandemic, the U.S. Justice Department said on Wednesday. The Justice Department said in a statement that a federal jury in New Jersey convicted Marc Schessel, 64, of two counts of securities fraud for public statements by SCWorx in April 2020, early in the pandemic, claiming that it was buying and reselling at least 48 million COVID-19 test kits, despite knowing that the statements were false.
NEW YORK, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- On May 17, 2024, SCWorx Corp. (the “Company”) received a further notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q for the period ended March 31, 2024, and because it remains delinquent in filing its Form 10-K for the year ended December 31, 2023, the Company has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1), which req
NEW YORK, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- On April 17, 2024, SCWorx Corp. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-K for the period ended December 31, 2023 with the Securities and Exchange Commission (“SEC”), the Company has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1) , which requires timely filing of all required periodic